DarioHealth Corp. (DRIO) 주식 분석

회사 개요

DarioHealth Corp. operates as a digital health enterprise serving markets both within the United States and internationally, leveraging a digital therapeutics platform to deliver personalized interventions driven by data analytics and one-on-one coaching for chronic conditions such as diabetes, hypertension, weight management, and musculoskeletal issues. The company functions within the broader Healthcare sector, specifically specializing in the Health Information Services industry, where it provides technology-enabled solutions to improve patient outcomes and operational efficiency for healthcare providers. As of the latest reporting period, DarioHealth Corp. maintains a total market capitalization of $51.83M and employs approximately 160 individuals to execute its strategic initiatives across its digital health portfolio. The annual revenue generated over the trailing twelve months stands at $22.36M, positioning the firm as a mid-sized player in the specialized digital therapeutics landscape. These valuation and revenue figures indicate that the company is a relatively small-cap entity with a focused operational scope, suggesting its financial trajectory is heavily dependent on the scalability of its digital platform and the adoption rates of its clinical solutions within the competitive health information services market.

재무 건전성

Over the trailing twelve months, DarioHealth Corp. recorded a revenue of $22.36M, yet reported a net income of -$40,309,576 and an EBITDA of -$33,517,000, highlighting a significant divergence between top-line growth and bottom-line profitability that reveals a challenging cost structure with substantial operating expenses. The company generated negative free cash flow of -$11,204,875 during the same period, which indicates limited financial flexibility for capital expenditures, strategic acquisitions, or dividend distributions without external financing. The gross margin stands at 64.1%, suggesting a favorable pricing power or cost of goods structure for its digital products, while the operating margin is deeply negative at -163.7% and the profit margin is -186.6%, signaling that overhead costs and general expenses far exceed gross profits. On the balance sheet, the company holds $26.02M in cash against $31.75M in debt, resulting in a debt-to-equity ratio of 46.74, which characterizes the capital structure as highly leveraged given the negative earnings base. Despite the leverage, the current ratio of 3.76 suggests that the company maintains a robust level of short-term liquidity relative to its current liabilities, providing a buffer against immediate payment obligations. Furthermore, the return on equity is -59.6% and the return on assets is -20.0%, metrics that reveal management is currently unable to generate positive returns on the shareholders' capital or the asset base due to the persistent net losses.

밸류에이션 평가

The valuation metrics for DarioHealth Corp. present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is reported at -16.32, implying that the market anticipates continued negative earnings in the near term. The price-to-book ratio is 0.72, indicating that the market is currently valuing the company at a discount relative to its tangible book value, which often occurs in distressed or turnaround situations. Alternative valuation metrics include a price-to-sales ratio of 2.32 and an EV/EBITDA of -1.72, suggesting that investors are pricing the stock based on revenue multiples rather than earnings power, likely due to the expectation of future profitability once operational costs stabilize. The 52-week price range spans from a low of $5.93 to a high of $17.74, and without a specific current price provided in the facts, the trading position relative to this range cannot be calculated, though the wide spread indicates significant price volatility over the past year. The stock exhibits a beta of 1.28, meaning that the share price is expected to be 28% more volatile than the broader market index, reflecting the high-risk profile associated with unprofitable growth stocks in the healthcare technology sector.

Growth & Income

Regarding growth dynamics, the company experienced a year-over-year revenue decline of -31.2%, while earnings growth is listed as N/A due to the absence of positive net income to measure against; this implies that the business is currently contracting rather than expanding in terms of top-line revenue generation. As a non-dividend payer, DarioHealth Corp. has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all available cash to fund operations and potentially reduce its debt burden rather than distributing income to shareholders. The absence of a dividend program is consistent with the company's financial profile, where reinvestment of capital is prioritized to address the negative free cash flow and improve the underlying economics of the digital therapeutics platform. Overall, the growth and income profile of DarioHealth Corp. is defined by revenue contraction and a lack of income distribution, reflecting a stage of business development where capital preservation and operational restructuring take precedence over shareholder returns.